Amicus Therapeutics: Cheap Heading Into 2025

Live Chat on The Biotech Forum has been dominated by discussion of lucrative buy-write or covered call opportunities on selected biotech stocks over the past several months. To see what I and the other season biotech investors are targeting as trading ideas real-time, just join our community at The Biotech Forum by clicking HERE .Shares of rare disease concern Amicus Therapeutics, Inc. ( NASDAQ: FOLD ) are down 15% since producing a profitable 3Q24 on a non-GAAP basis that compelled management to raise its ...